23041-Myeloproliforative Disorder-NA-607

Myeloproliforative Disorder

Randomized, open-label, multicenter phase 3 study to assess the efficacy and safety of GIVinostat versus hydroxyurea IN JAK2V617F-positive high-risk Polycythemia Vera patients: the GIV-IN PV TRIAL (DSC/08/2357/32)

  • Details

ClinicalTrials.gov ID: NCT06093672
Diagnosis Type: NA
USOR Number:

  • Address


,
P:

Search by practice name, trial titles, indicators and specific disease types.